AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. – 48. (Canceled)

49. (Previously Presented) A method for preventing and/or treating a respiratory syncytial virus (RSV)-induced disease, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds a RSV antigen with an affinity constant (K_a) of at least $10^{10}\,M^{-1}$ as measured by surface plasmon resonance.

50. (Previously Presented) A method for preventing and/or treating a RSV infection, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds to a RSV antigen with a K_a of at least $10^{10}\,M^{-1}$ as measured by surface plasmon resonance.

51. (Previously Presented) The method of claim 49, wherein the K_a is at least $10^{11}\,M^{-1}$.

52. (Previously Presented) The method of claim 50, wherein the K_a is at least 10^{11} M^{-1}.

53. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an IC_{50} in a microneutralization assay that is less than the IC_{50} of the reference antibody IX-493.

54. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an IC_{50} of 2 μg/ml to 10 μg/ml in a microneutralization assay.

55. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin specifically binds to a RSV F antigen.

56. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin binds to the same epitope on RSV as the antibody composed of a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO:2 (Figure 1B) and a light chain variable region (VL) having the amino acid sequence SEQ ID NO:1 (Figure 1A).

57. – 72. (Cancelled)

73. (Currently Amended) The method of claim 51 or 52, wherein the high affinity neutralizing immunoglobulin comprises:

a. a VH CDR1 having the amino acid sequence TAGMSVG (SEQ ID NO:9);
b. a VH CDR2 having the amino acid sequence DIWWDDKKDYNPSLKS (SEQ ID NO:7);
c. a VH CDR3 having the amino acid sequence SMITNFYFDV (SEQ ID NO:11);
d. a VL CDR1 having the amino acid sequence SASSSVGYMH (SEQ ID NO:3);
e. a VL CDR2 having the amino acid sequence DTFKLAS (SEQ ID NO:12); and
f. a VL CDR3 having the amino acid sequence FQGSFYPFT (SEQ ID NO: 14) ~~or FQGSYYPFT (SEQ ID NO:15)~~.

74. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an $F(ab)'_2$, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

75. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a humanized antibody.

76. – 78. (Cancelled)

79. (Previously Presented) The method of claim 73, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an $F(ab)'_2$, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

80. – 82. (Cancelled)

83. (Previously Presented) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:24.

84. (Cancelled)

85. (Previously Presented) The method of claim 49 or 50, wherein the subject is a human.